Navigation Links
Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
Date:2/27/2008

he results of the prior year.

Gross profit for the nine months ended December 31, 2007 was $874.4 million and gross margins were 40.1%. The decrease in gross margins is due primarily to the effects of purchase accounting items of approximately $148.9 million. Excluding such items, gross margins were 47.0% compared to 54.1% for the nine months ended December 31, 2006.

The loss from operations for the nine months ended December 31, 2007 was $988.3 million as a result of the purchase accounting items discussed above and the one-time charge to write-off acquired in-process research and development. Excluding these amounts, earnings from operations would have been $429.7 million for the nine month period, a decrease of $5.7 million from the prior year.

R&D expense for the nine months ended December 31, 2007, excluding that incurred by newly acquired entities, was $74.9 million compared to $66.8 million in the same prior year period, an increase of $8.1 million or 12%.

SG&A expense, also excluding amounts contributed by new entities, increased by $95.1 million or 62% to $247.9 million compared to $152.8 million in the comparable prior year period. The majority of this increase was realized by Corporate and Other, and is the result of costs, such as professional and consulting fees, associated with the integration of Merck Generics, as well as higher payroll and related costs principally attributable to the build-up of additional corporate infrastructure as a direct result of the Merck Generics acquisition.

Interest expense for the nine months ended December 31, 2007 totaled $179.4 million compared to $31.3 million for the nine months ended December 31, 2006. The increase is due to the additional debt incurred to finance the acquisition of Merck Generics.

Other income (expense), net was income of $86.6 million for the nine months ended December 31, 2007, compared to income of $39.8 million in the same prior year period. The most si
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
2. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
3. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
4. Mylan Restores Availability of Generic Levothyroxine in Florida
5. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
8. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
9. Mylan Sets Date of 2008 Annual Meeting
10. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
11. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (Boston)--Minority women who received the Human Papillomavirus Vaccination ... rates of abnormal Pap test results than those ... the journal Sexually Transmitted Diseases . ... Health and School of Medicine conducted a cross-sectional ... undergoing routine cervical cytology testing. HPV status and ...
(Date:7/24/2014)... New York, New York (PRWEB) July 24, 2014 ... a testosterone lawsuit ( http://www.drugbot.com/testosterone/lawsuit/ ) against the ... informed of the risks associated with the low ... action complaint, which was filed in the Ontario ... further alleges that use of low testosterone therapy ...
(Date:7/24/2014)... new formulation of a powerful narcotic painkiller that discourages ... been approved by the U.S. Food and Drug Administration. ... the pill is a combination of the narcotic oxycodone ... of oxycodone. The naloxone is only activated when the ... the FDA. While Targiniq has only been approved ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 ACRIA & AMIDA ... BROOKS, , Save the Dates: August 7th ... are excited to cohost “A Dialogue for Life” forums this ... the White House Office of National AIDS Policy (ONAP). This ... efforts being made locally by AIDS organizations, consumers and advocates ...
(Date:7/24/2014)... For the first time in her career, Susan Boyle ... first became a known musical commodity after appearing on the British ... show was “I Dreamed a Dream,” from Les Misérables and the ... her time on the reality show in 2009 and now feels ... fans. The tour will kick off on October 8 at the ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 3Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 2Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 4
... By Amanda Gardner HealthDay Reporter , TUESDAY, June ... on Monday, a new study concludes there is no increased ... diabetes drug Avandia. This latest finding even suggests that ... of heart attack, stroke or death in certain settings, compared ...
... studies have found that the personality trait impulsivity, ... behaviors, is associated with alcohol use and alcohol-use ... and young adulthood. Some, however, do not "mature ... have found that individuals who exhibited the largest ...
... Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ... beginning in January 2006. This has dramatically reshaped the ... on insurers, beneficiaries, and providers. For researchers, it has ... A special themed issue of Research in Social ...
... ... Approved Total Artificial Heart a Reality , ... Tucson, Ariz. (Vocus) June 29, 2010 -- On July 1, Total Artificial Heart ... new $227 million Sulpizio Family Cardiovascular Center at the University of California, San Diego in ...
... ... Automatic Placement of Access Points to Simplify Planning and Budgeting for Wi-Fi Deployments. , ... Santa Clara, CA (PRWEB) June 29, ... architecture, announced today that it has released a new version of its free Online Wi-Fi ...
... University of Nottingham are spearheading a new project to reduce ... highest rates of smoking in the country. Funded by ... local community champions to challenge the general acceptance of smoking ... quit. Nottingham has the 3rd highest rate of smoking ...
Cached Medicine News:Health News:Latest Study on Diabetes Drug Avandia Finds No Heart Risks 2Health News:Latest Study on Diabetes Drug Avandia Finds No Heart Risks 3Health News:Large decline in impulsivity in early adulthood related to decrease in alcohol consumption 2Health News:Experts analyze benefits, opportunities and challenges of Medicare Part D 2Health News:Experts analyze benefits, opportunities and challenges of Medicare Part D 3Health News:World Renowned Total Artificial Heart Pioneer Dr. Jack Copeland Joins Faculty at UC San Diego 2Health News:World Renowned Total Artificial Heart Pioneer Dr. Jack Copeland Joins Faculty at UC San Diego 3Health News:Aerohive Networks Releases New Version of Free Wi-Fi Planning Tool 2Health News:Aerohive Networks Releases New Version of Free Wi-Fi Planning Tool 3Health News:A community approach to kicking the habit 2Health News:A community approach to kicking the habit 3Health News:A community approach to kicking the habit 4
(Date:7/24/2014)... /PRNewswire-iReach/ -- "North America Orthopedic Braces and Supports Market ... North America Orthopedic Braces and Supports market. The report ... (in units) and average price data (in US dollars), ... Supports , Ankle Braces and Supports , ... and Supports. Photo - ...
(Date:7/24/2014)... -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today ... 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 ,  Percentage ... 51% Non-GAAP Net Sales , $278.8 Million , $196.1 ... , $1.12 , 37% Non-GAAP Diluted ... 37%  Six Months Ended 06/30/14Six Months Ended 06/30/13 , ...
(Date:7/24/2014)... 24, 2014  To help health care organizations ... could impact patient care and the bottom line, ... , "Innovations in Cardiovascular Devices."  ... and details on promising new technologies that can ... how these options impact the supply chain.   According ...
Breaking Medicine Technology:North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3
...  TSH testing, the gold standard in hypothyroid diagnosis, may ... new article titled Hormone Replacement Therapy in ... Questions for the Future. Estrogen, Progesterone, Testosterone, and Thyroid ... article, independently written and published, is a broad study ...
... Jan. 2, 2012 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... call on Tuesday, January 3, 2012 at 8:30 a.m. Eastern ... ongoing patent litigation with Genentech, Inc., a member of the ... Conference Call InformationDomestic Dial-in Number: (888) 660-6127 International Dial-in Number: ...
Cached Medicine Technology:Studies Show That TSH Is Unreliable in the Diagnosis of Hypothyroidism According to Article Contributed by Kent Holtorf, M.D. in Clinical Geriatrics 2Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation 2
... TraceMasterVue is a cutting-edge ... rich, thin-client functionality and convenient, ... clinical, administrative and information technology ... productivity, lower costs, and improved ...
... testing within reach of virtually any facility...from ... most advanced cardiology hospital. This PC-based system ... options for a Philips ergonomic stress cart ... StressVue is designed to interface with the ...
A component of the 3M Littmann Electronic Stethoscope Model 4000...
... with the challenge of,controlling costs while ... patient data,management is critical. INFINITY modular,patient ... important clinical information,wherever you are in ... concept,makes your job easier. You can ...
Medicine Products: